We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $542M
1-Year Est. Return 206.64%
This Fund
S&P 500
This Quarter Est. Return
+28.45%
1 Year Est. Return
+206.64%
3 Year Est. Return
+724.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$542M
AUM Growth
+$42.4M
Cap. Flow
+$30.9M
Cap. Flow %
5.7%
Top 10 Hldgs %
64.55%
Holding
57
New
7
Increased
11
Reduced
3
Closed
9

Top Buys

Rank Stock Value
1
BTSG icon
BrightSpring Health Services
BTSG
+$25.7M
2
ALKS icon
Alkermes
ALKS
+$17.5M
3
TVTX icon
Travere Therapeutics
TVTX
+$11.9M
4
RVMD icon
Revolution Medicines
RVMD
+$8.82M
5
CELC icon
Celcuity
CELC
+$5.05M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$35.2M
2
ABVX
Abivax
ABVX
+$9.54M
3
TERN
Terns Pharmaceuticals
TERN
+$5.53M
4
INSM icon
Insmed
INSM
+$4.8M
5
ABBV icon
AbbVie
ABBV
+$3.15M

Sector Composition

Rank Sector Weight
1 Healthcare 97.08%
2 Miscellaneous 2.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVTX icon
51
Avalo Therapeutics
AVTX
$1.06B
– –
-28,970
Closed -$433K
BBIO icon
52
BridgeBio Pharma
BBIO
$14.6B
– –
-20,400
Closed -$1.51M
INSM icon
53
PUT
Insmed
INSM
$27.3B
– –
-279,700
Closed -$45.7M
LLY icon
54
Eli Lilly
LLY
$1T
– –
-38,220
Closed -$35.2M
MRNA icon
55
CALL
Moderna
MRNA
$56B
– –
-200,000
Closed -$10.2M
SLNO
56
DELISTED
Soleno Therapeutics
SLNO
– –
-68,490
Closed -$2.29M
TERN
57
DELISTED
Terns Pharmaceuticals
TERN
– –
-104,800
Closed -$5.53M
1 2
3

Similar funds

CA
CV Advisors Aventura, Florida $542M AUM 24.89% 1-Year Est. Return
WCM
Westerly Capital Management San Francisco, California $542M AUM 48.48% 1-Year Est. Return
LI
Louisbourg Investments Dieppe, New Brunswick, Canada $542M AUM 21.44% 1-Year Est. Return
CWWM
Clear Wave Wealth Management Red Bank, New Jersey $541M AUM
FVCM
F&V Capital Management Boca Raton, Florida $542M AUM 46.38% 1-Year Est. Return
LI
Lafayette Investments Ashton, Maryland $542M AUM 22.5% 1-Year Est. Return
CCT
Chemung Canal Trust Elmira, New York $541M AUM 32.42% 1-Year Est. Return
MFS
Madrona Financial Services Everett, Washington $543M AUM 30.87% 1-Year Est. Return

Artia Global Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Artia Global Partners held 57 positions worth $542M, up 8.5% from $499M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Artia Global Partners deployed $30.9M of net new capital in Q2 2026, opening 7 new positions and adding to 11 existing holdings. Its largest new stake was Alkermes: 448,964 shares worth $23.5M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 89% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Abivax, an estimated $9.54M trimmed.

  • Artia Global Partners's largest Q2 2026 buy was Alkermes: 448,964 shares worth $23.5M.
  • Artia Global Partners added most to BrightSpring Health Services in Q2 2026, an estimated $25.7M increase.
  • Artia Global Partners's biggest Q2 2026 reduction was Abivax, cutting an estimated $9.54M.
  • Artia Global Partners fully exited Eli Lilly in Q2 2026, selling an estimated $35.2M.
  • Artia Global Partners's ten largest holdings make up 65% of its $542M portfolio in Q2 2026.
  • Artia Global Partners opened 7 new positions and closed 9 in Q2 2026.
  • Artia Global Partners's portfolio value rose 8.5% quarter-over-quarter to $542M.

Based on Artia Global Partners's 13F filing for Q2 2026, filed 14 Aug 2026.